BamSEC and AlphaSense Join Forces
Learn More

Can-Fite Biopharma Ltd Sponsored

NYSE American: CANF    
Share price (1/8/25): $1.57    
Market cap (1/8/25): $8.745 million
Search in Documents
Key Exhibits
External Links

Latest Filings – Non-Ownership Filter

6-K
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite’s Anti-Cancer Drug Namodenoson
12/30/24
6-K
8 Years Survival With Complete Cure for a Patient With Advanced Liver Cancer Being Treated With Can-Fite’s Namodenoson Drug
12/04/24
6-K
Achieves Milestone With First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
11/12/24
6-K
Anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
11/04/24
6-K
Significant Positive Results From Osteoarthritis Clinical Study in Dogs Treated With Piclidenoson Data Reported by Can-Fite Veterinary Partner Vetbiolix Who Already Exercised Its Option for a Full License Deal Worth $325M
10/18/24
6-K
### ###### ###### #### ########### ## ########## ########### ### ########## ######
10/09/24
6-K
######### ###### ## ##### ## ######## #### ### #### ## ##### ##### ######### ######### ### ###### ### ######## ############ ### ########## ##############
09/24/24
6-K
######### ########## ######### ##### ### ######## ##### #### ########### ######## ########## ############# #### ### ####### ######## ## ######
09/16/24
EFFECT
###### ## #############
09/06/24
424B3
########## ##########
09/06/24
CORRESP
############## #### ### ###
09/06/24
EFFECT
###### ## #############
09/05/24
UPLOAD
###### #### ### ###
09/05/24
6-K
######## ##########
08/30/24
F-3
##### ############
08/30/24
POS AM
####### #### ### ################# ##########
08/30/24
424B5
########## ########## ### ####### ########
08/30/24
6-K
######### ### ######### ###### ### #########
08/29/24
6-K
######## ##########
08/12/24
6-K
######### ######## ## ######## ### ############# #### ####### ## ##### ########
08/09/24

Latest Filings – Ownership Filter